Karmanos Adds FDA-Approved Daraxonrasib for Metastatic Pancreatic Cancer
Event summary
- Karmanos Cancer Institute now offers daraxonrasib (Rasonque), an FDA-approved oral therapy for metastatic pancreatic cancer, following the Aug. 26, 2026 approval.
- The approval was supported by the phase III RASolute 302 trial, in which Karmanos participated, showing median overall survival of 13.2 months with daraxonrasib vs. 6.7 months with standard chemotherapy.
- Daraxonrasib targets active forms of the RAS family of proteins, key drivers of tumor growth in most pancreatic adenocarcinomas.
- The National Cancer Institute estimates 67,530 new cases of pancreatic cancer in the U.S. in 2026, with 51% diagnosed at the metastatic stage.
The big picture
The approval of daraxonrasib marks a significant advancement in the treatment of metastatic pancreatic cancer, a disease with historically limited therapeutic options. Karmanos' involvement in the pivotal trial underscores its role as a leader in oncology innovation, particularly in targeted therapies. The FDA's decision could accelerate the development of similar treatments, reshaping the competitive landscape for pancreatic cancer therapies.
What we're watching
- Adoption Pace
- How quickly Karmanos and other institutions will integrate daraxonrasib into standard treatment protocols for metastatic pancreatic cancer.
- Market Impact
- Whether the approval will drive further investment in RAS-targeted therapies and expand the pipeline for similar treatments.
- Long-term Efficacy
- The extent to which daraxonrasib's survival benefits translate into real-world outcomes beyond the clinical trial setting.
Related topics